NASH's new drug is certified as GLP-1/GCCR dual agonist by FDA fast track qualification

On June 2, Boehringer Ingelheim and Zealand Pharma jointly announced that the FDA has granted GLP-1/glucagon receptor (GCCR) dual agonist BI 456906 fast track designation for adult non-alcoholic steatohepatitis ( NASH).

BI 456906 is derived from the natural intestinal hormone oxyntomodulin, which can activate GLP-1 and glucagon receptors that are essential for controlling metabolic functions.

Currently, BI 456906 is conducting a randomized, double-blind, placebo-controlled Phase II clinical study (NCT04771273) to evaluate the efficacy of the drug in adult patients with NASH and liver fibrosis (F2/F3).

In China, Boehringer Ingelheim submitted a clinical application as early as December 22, 2020, and has launched an international multi-center phase 2 clinical trial for obese patients.

Domestic progress of BI 456906 project

From the Insight database (http://db.

Non-alcoholic steatohepatitis (NASH) is one of the main causes of liver fibrosis and cirrhosis.

Note: The original text has been deleted